Electric excitation initiates myocardial mechanical contraction and coordinates myocardial pumping. We hypothesized that ECG global electric heterogeneity (GEH) and its longitudinal changes are associated with cardiac structure and function.
T
he heart is an electric generator and electromechanical pump. 1 Electric excitation initiates mechanical contraction, orchestrates excitationcontraction coupling, 1 and coordinates myocardial pumping. Changes in the frequency, 2 regularity, 3 and order 4 of cardiac electric excitation can cause electric heterogeneity, dyssynchrony, ventricular dysfunction, and ultimately clinical pump failure. [2] [3] [4] Although the molecular biology of excitation-contraction coupling is well understood, 1 and mechanisms of dyssynchronyinduced cardiomyopathy are recognized, its prognostic markers are not identified. 5 Additionally, there is no inexpensive and widely available method for monitoring the degree of or changes in electric dyssynchrony over time.
Recently, we described ECG parameters depicting global electric heterogeneity (GEH). 6 The GEH concept is based on the theory of Wilson electric gradient vector, 7 which characterizes the degree of heterogeneity of total recovery time 8 across the ventricles and points toward the area where the total recovery time is shortest. Five vectorcardiographic parameters (spatial QRS-T angle, sum absolute QRS-T integral [SAI QRS-T], spatial ventricular gradient [SVG] vector magnitude, azimuth, and elevation) characterize GEH. 6 We recently showed that GEH characterizes an electrophysiological substrate independently associated with the risk of sudden cardiac death (SCD). 6 However, the relationships between GEH and cardiac structure and function have not been previously studied and have not been compared with traditional global ECG parameters (QRS and QTc intervals and ECG left ventricular hypertrophy [LVH] measures). We hypothesized that GEH is associated with echocardiographic measures of cardiac structure and function in the general community population with and without ventricular conduction abnormalities, LVH, and cardiovascular disease (CVD). We also hypothesized that longitudinal patterns of GEH changes over time differ in participants with different clinical outcomes (with versus without left ventricular (LV) dysfunction, SCD, non-SCD, and noncardiac death).
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Sample
The ARIC study (Atherosclerosis Risk in Communities) is an ongoing, prospective cohort study evaluating risk factors, progression, and outcomes of atherosclerosis in 15 792 participants (45% male; 74% white) enrolled in 4 United States communities in 1987 to 1989. ARIC study design and protocol have been previously described. 9 Follow-up of
WHAT IS KNOWN?
• Myocardial global electric heterogeneity (GEH) can be measured on a standard 12-lead ECG through vectorcardiographic parameters (spatial QRS-T angle, spatial ventricular gradient, and sum-absolute QRS-T integral).
• Abnormal increases in GEH parameters are independently associated with sudden cardiac death in an adult community-dwelling population.
WHAT THE STUDY ADDS?
• GEH reflects subclinical abnormalities in cardiac structure and function and represents one mechanism by which abnormal electrophysiological substrate may lead to an increased risk of left ventricular dysfunction and sudden cardiac death.
• Healthy aging in spite of a lifelong cardiovascular disease risk factor exposure is characterized by longitudinal changes in spatial ventricular gradient azimuth, manifest as posterior rotation of the spatial ventricular gradient vector.
• Slow worsening of GEH over time is associated with subsequent left ventricular dysfunction, whereas rapid worsening of GEH is associated with an increased risk of sudden cardiac death.
ARIC participants included 3 triennial visits through 1998; each visit included a 12-lead ECG recording. 10 A fifth examination was conducted between June 1, 2011, and August 30, 2013. Out of 10 740 surviving participants, 6538 participants (now aged 67-91 years) attended visit 5, and 6118 underwent echocardiography, whereas 5981 underwent 12-lead ECG recording at rest. The study protocol was approved by institutional review boards at each field center, and all participants signed informed consent.
Our cross-sectional study sample included ARIC cohort participants who underwent both echocardiography and 12-lead ECG during visit 5 (on the same day) with echocardiographic images and ECG recordings of acceptable quality for analysis, and the ability to measure GEH. We excluded participants with reported race other than white or black (n=18), without echocardiographic examination (n=598), with atrial fibrillation at the time of echocardiography, with absent or uninterpretable ECGs (n=162), and with missing covariates (n=272). The final study population included 5114 participants with analyzable data on cardiac structure and function and ECG GEH. In addition, longitudinal analysis included all ARIC cohort participants (N=14 609) with measured GEH at visits 1 to 4, as reported previously. 6 
Definition of Clinical Covariates
For cross-sectional analysis, demographic and clinical characteristics were assessed at the time of the fifth visit. Coronary heart disease (CHD) was defined as a history of myocardial infarction, a history of angina pectoris, or a history of coronary revascularization (either via coronary artery bypass surgery or percutaneous coronary intervention). At baseline (visit 1), history of myocardial infarction was defined by participant self-report. At subsequent visits, it was defined as baseline history plus adjudicated events between baseline and the visit of interest. Heart failure (HF) 11 was defined as evidence of symptomatic HF as defined by stage 3 of the Gothenburg criteria, 12 which required the presence of specific cardiac and pulmonary symptoms in addition to medical treatment of HF, self-reported use of HF medications, an adjudicated HF hospitalization (since 2005), or HF hospitalization with International Classification of Diseases, Ninth Revision, code 428x (before 2005). Hypertension was defined as a systolic blood pressure (BP; average between second and third measures) of ≥140 mm Hg, a diastolic BP ≥90 mm Hg, or physician-reported history of hypertension and use of antihypertensive medications. Diabetes mellitus (DM) was defined as a nonfasting glucose level of at least 200 mg/dL, a fasting (≥8 hours) glucose level of ≥126 mg/ dL, a self-reported diagnosis of DM, or the use of diabetic medications.
Concentrations of high-sensitivity cTnT (cardiac troponin T) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) were measured as previously described 13 at the fourth (1996-1998) and fifth (2011-2013) study visits.
For longitudinal analyses, we used time-updated clinical covariates: incident CHD, HF, DM, and hypertension. Follow-up of the study participants included annual telephone calls, local hospital surveillance, 3 triennial visits through 1998, and the fifth study visit (2011-2013), as previously reported. 10 Incident HF was diagnosed as first HF hospitalization with International Classification of Diseases, Ninth Revision, code 428.0 to 428.9 in any position of the hospital discharge list and characteristic signs and symptoms of congestion, characteristic chest x-ray findings, and assessment of LV function.
14 Incident CHD was defined as a definite or probable myocardial infarction, angina, or a coronary revascularization procedure. 6 Risk factors (body mass index, smoking status, total cholesterol, high-density lipoprotein, triglycerides, and systolic and diastolic BP) were assessed at each visit.
Assessment of GEH and Traditional ECG Characteristics on ECG
GEH was quantified by 5 parameters, as previously described 6 ( Figure I in the Data Supplement). Spatial mean QRS-T angle was measured as a 3-dimensional angle between the mean QRS-and T-vectors. 15 The magnitude and direction (azimuth and elevation) of the mean SVG vector (vectorial sum of the mean QRS-and the mean T-vectors) were determined. 6 SAI QRS-T was computed as the arithmetic sum of areas under the QRS-T curve on XYZ leads, with baseline defined as the voltage at the end of the T-wave. 16, 17 Because SVG magnitude is largely independent of the specific ventricular activation sequence, 18 we did not exclude participants with ventricular conduction abnormalities. Sex-and race-specific thresholds were used to define abnormal GEH parameters, as previously described. 6 Heart rate, corrected QT interval (QTc), and QRS duration were measured on the median beat by the General Electric 12SL algorithm (GE Marquette, Milwaukee, WI). Prolonged QTc was defined as exceeding 450 ms in men and 470 ms in women. 19 Sex-specific Cornell product was calculated for the assessment of ECG-LVH (>2440 mm*ms). 20 Presence of ventricular conduction abnormalities were defined by the Minnesota Code (MC) 21 (left bundle branch block MC 7.1, right bundle branch block MC 7.2 and 7.3, fascicular block MC 7.6-7.7, and bifascicular block MC 7.8) or ventricularpaced rhythm.
We measured GEH and traditional ECG parameters on all ECGs recorded during visits 1 to 5.
Assessment of Cardiac Structure and Function on Echocardiogram
Details of the echocardiographic imaging and analysis protocol have been thoroughly described previously. 22 All echocardiograms were acquired during visit 5 with a dedicated machine (Phillips iE33 Ultrasound systems with Vision 2011) per a detailed acquisition protocol that included comprehensive 2-dimensional, Doppler, tissue Doppler, and speckle-tracking echocardiography. 22 Heart rate and systolic and diastolic BP were measured at the time of echocardiography. Dedicated and blinded analysts at the Brigham and Women's Hospital Cardiac Imaging Core Laboratory performed quantitative measures on all echocardiograms according to American Society of Echocardiography recommendations and standards. 23, 24 LV volumes and the LV ejection fraction (LVEF) were assessed using the modified Simpson rule.
Cardiac structure measurements included LV end-diastolic volume, LV end-systolic volume, and LV mass index (LVMi).
LV dimensions and mass were indexed to body surface area as per American Society of Echocardiography guidelines. 23, 24 As recommended, LV end-diastolic volume index (LVEDVi) >74 mL/m 2 24 Systolic LV function measurements included LVEF and global longitudinal LV strain (GLS) derived from speckle-tracking echocardiography. Speckle-tracking analysis was performed using Tom-Tec Cardiac Performance Analysis package (TomTec, Unterschleissheim, Germany). GLS was obtained from apical 4-and 2-chamber views, as previously described. 22 LVEF of <52% for men and <54% for women was defined as abnormal. 24 Peak GLS >−14% was considered abnormal.
24,25

Statistical Analysis
All continuous variables are presented as means±SD. Square-root-transformed SVG elevation and squareroot-transformed absolute SVG azimuth were used in all adjusted analyses to normalize distribution of these 2 circular variables. Because of a U-shaped association between SVG magnitude and echocardiographic parameters, we squared SVG magnitude for its entry as a predictor in linear regression models.
Comparison of Visit 5 Responders to Alive Visit 5 Nonresponders
To determine how ARIC study participants who participated in visit 5 (visit 5 responders) are similar to alive ARIC study participants who did not participate in visit 5 (visit 5 nonresponders), we compared baseline (visit 1) clinical characteristics of visit 5 responders versus visit 5 nonresponders, using t test and χ 2 test, as appropriate.
Cross-Sectional Analyses
ANOVA was used for unadjusted comparisons of LV structure and function in participants with abnormal GEH parameters. To assess continuous relationships between ECG and echocardiographic measures, we used multivariable linear regression models. Each ECG predictor variable was entered into a separate regression model. To answer whether cross-sectional associations between ECG and LV structure and function were mostly because of prevalent or subclinical CVD, we constructed multiple models. Model 1 was minimally adjusted for age, sex, and race. Model 2 was additionally adjusted for known confounders of cardiac structure and function 26, 27 : CHD, HF, hypertension, DM, body mass index, smoking, presence of ventricular conduction abnormalities, and heart rate and systolic and diastolic BP measured at the time of echocardiography. Model 3 was additionally adjusted for QRS duration. Standardized β coefficients were used to compare the strength of the association across ECG predictors, reflecting the change of outcome variable per 1 SD of each ECG predictor variable increase. Subgroup analysis was performed in model 2 to determine significant interactions between ECG parameters and clinical characteristics in their effect on LV structure and function. In addition, associations between ECG and echocardiographic parameters were also evaluated using fully adjusted (model 2) multivariable linear regression models incorporating cubic splines with 4 knots.
Longitudinal Analysis I: Comparison of Longitudinal ECG Changes in Participants Who Did Versus Did Not Develop LVH, LV Dilatation, and Systolic Dysfunction
To determine whether longitudinal changes in ECG parameters were associated with LV structure and function, we performed several longitudinal analyses. First, a t test was used to compare differences in baseline (measured at visit 1) ECG parameters in participants with versus without LV systolic dysfunction, dilatation, or hypertrophy, as diagnosed by echocardiography at visit 5 (median 24 years later). Next, we compared patterns of visit-to-visit changes in ECG parameters over time (from visit 1 to visit 5) in participants who did versus did not develop LVH, LV dilatation, and systolic dysfunction. Generalized estimating equations were used to fit population-averaged generalized linear models. Within-participant correlation structure was estimated as autoregressive of order 1. The canonical link function for the Gaussian family was used. Robust SE was reported. Time-updated ECG variables served as continuous timeupdated outcomes. Separate models were constructed for each ECG variable.
To answer the question of whether LVH, LV dilatation, and LV systolic dysfunction were associated with different patterns of ECG changes over time, these binary echocardiographic variables were entered in the models one-by-one. The pattern of dynamic ECG changes was described in each subgroup: in participants with and without LVH, LV dilatation, and systolic dysfunction. All linear generalized estimating equations models were rigorously adjusted for time-updated confounders representing known pathways of myocardial injury. Model 1 was adjusted for sex and race. Model 2 was in addition adjusted for prevalent and incident HF and CHD. Model 3 was further adjusted for all time-updated covariates (DM, hypertension, body mass index, current smoking status, levels of total cholesterol, high-density lipoprotein, triglycerides, systolic and diastolic BP, heart rate, presence of ventricular conduction abnormalities, high-sensitivity cTnT, and NT-proBNP, and age) and exact time interval (in days) between each ECG recording.
Longitudinal Analysis II: Comparison of ECG Change Patterns in Healthy Aging Participants Versus Those Who Developed LVH, LV Dilatation, LV Systolic Dysfunction, or Died Because of SCD, Non-SCD, or Noncardiac Death
We performed a comparison of longitudinal ECG changes in ARIC study participants who died because of SCD, non-SCD, and noncardiac death before the fifth visit and those who survived and were diagnosed with LV systolic dysfunction, LVH, and LV dilatation on the fifth visit echocardiogram. For appropriate comparison, in survivors, we used patterns of changes in ECG parameters from visit 1 to visit 4 (median, 12 years). Linear generalized estimating equations models were constructed in 3 subgroups of competing death outcomes 6 and 5 LV dysfunction subgroups. All models were adjusted for sex and race.
Statistical analyses were performed using STATA MP 15.0 (StataCorp LP, College Station, TX). We applied the Bonferroni correction for multiple testing. Because we tested 8 predictors and 5 outcomes, a P value <0.00125 (0.05/40) was considered statistically significant.
RESULTS
Study Population
Clinical characteristics of the study participants (obtained at visit 5) are shown in Table. Prevalent CHD and HF were infrequent, whereas CHD risk factors were common. LV systolic function and LV volumes were within the normal range in most participants. Approximately 10% of participants had ECG-LVH. Abnormal GEH was observed more frequently than traditional ECG abnormalities: two thirds of participants had at least one abnormal GEH parameter, and 38% of participants had at least 2 abnormal GEH parameters. No participants had abnormal SVG magnitude.
Comparison of Visit 5 Responders to Alive Visit 5 Nonresponders
Visit 5 nonresponders compared with responders were older, were more likely to be female and black, and had higher rates of prevalent CVD and CVD risk factors (Table) . Nevertheless, there were no significant differences in most baseline ECG GEH parameters between these 2 groups, with a few exceptions. SVG magnitude and SAI QRS-T were significantly smaller in visit 5 nonresponders in spite of significantly longer QTc and larger Cornell product (Table) .
Cross-Sectional Association of Global ECG Measures With LV Structure and Systolic Function at Study Visit 5
In unadjusted analyses, the number of abnormal GEH parameters was associated with LV systolic function, LV volumes, and LV mass indices (Figure 1 ). In adjusted regression analyses, all ECG metrics at visit 5 were robustly associated with echocardiographic measures of cardiac structure and systolic function at visit 5, except SVG magnitude, which did not associate with LVEF ( Figure 2 ). All GEH ECG variables were monotonically associated with echocardiographic metrics (Figure 3 ; Figures II through V in the Data Supplement). Adjustment for prevalent and subclinical CVD only slightly attenuated the strength of these associations, suggesting an independent cross-sectional association between ECG GEH characteristics and LV structure and function, although the strength of associations ranged from negligible to weak (Figure 2 ). Further adjustment for QRS duration confirmed an independent association between GEH and LV structure and function and revealed differences between the 5 GEH parameters. QRS duration fully explained the associations of SVG elevation with GLS and of SVG azimuth with LV volumes ( Figure 2 ).
Higher GEH was significantly associated with worse LV systolic function (Figure 2 ). For every 10 ms increase in QRS duration, LVEF (Figure 3 ) decreased by 1% (95% confidence interval [CI], 0.9-1.1%). Every 100 mV*ms increase in SAI QRS-T was associated with a 2% (95% CI, 1.6-2.1%) LVEF drop. The presence of ECG-LVH was associated with a 3% (95% CI, 2.4-3.6) LVEF reduction and having 4 abnormal GEH parameters was associated with a 6.4% (95% CI, 5.5-7.3) LVEF decline. SAI QRS-T had a strong association with GLS ( Figure II in the Data Supplement). Although each ECG measure separately explained a relatively small proportion (≈10%) of population-level variability of LV systolic function parameters, altogether, ECG and clinical characteristics were responsible for ≈20% of systolic function variability ( Figure 2 ).
Cross-sectional associations between GEH and LVMi were stronger than those between GEH and LV systolic function (Figure 2 ; Figure III 
Subgroups Analyses
We observed numerous interactions between ECG parameters and clinical characteristics in their effect on LV echocardiographic measures of cardiac structure and function (Table I in the Data Supplement). Overall, the associations between ECG parameters and LV structure and function were stronger in the subgroups of participants with prevalent and subclinical CVD (Figure 4 ; Figures VI through VIII in the Data Supplement), with few exceptions. SAI QRS-T was more strongly associated with LVEDVi and LV end-sys-tolic volume index in hypertension-free participants and individuals with normal conduction, compared with hypertensive participants and those with conduction abnormalities (Table I in the Data Supplement). Cornell product was more strongly associated with LVEF in CHD-free participants compared with those with CHD ( Figure 4) .
Association of Longitudinal Changes in ECG Parameters Over 24 Years With LV Structure and Function
Measurement of visit 1 baseline ECG parameters was performed 23.6±1.0 years before the echocardiographic assessment of LV structure and function. Study participants with LV systolic dysfunction and abnormal LV end-systolic volume index at visit 5 had wider (by 12 degrees) baseline QRS-T angles and larger (by 20 mV*ms) SAI QRS-T (Table II in the Data Supplement) . SVG elevation (but not azimuth or magnitude) was also different ≈24 years before the diagnosis of LV systolic dysfunction. Differences in QRS duration (3 ms) were statistically significant but small. Of note, baseline GEH parameters (especially SAI QRS-T) did not differ in individuals with versus without echo-LVH, which was diagnosed 24 years later. In contrast, baseline Cornell product was significantly larger in the subgroup with echo-LVH (Table II in Table III in the Data Supplement) showed that patterns of longitudinal changes in all but one ECG parameter were significantly and dramatically different in participants with normal versus abnormal LV structure and function. The pattern of temporal SVG magnitude changes, however, was an exception: it slightly and monotonically decreased in all individuals. SAI QRS-T did not change in healthy aging participants. In contrast, SAI QRS-T increased on average by 20 mV*ms over each 3-year period in participants who demonstrated LV dilatation at visit 5. Similar patterns were confirmed for longitudinal changes of QRS-T angle (≈10 degrees/3 years), SVG azimuth and elevation, Cornell product (≈200 mm*ms/3 years), and QTc intervals (5-8 mm/3 years). Systolic dysfunction and LV dilatation were associated with larger longitudinal changes in GEH ECG parameters, whereas echo-LVH was associated with smaller longitudinal ECG parameter changes.
Longitudinal ECG changes in participants who developed LV systolic dysfunction, LVH, and LV dilatation were fully explained by clinically manifest and subclinical CVD and subclinical myocardial injury ( Figure 6 ; Table  III in the Data Supplement). In contrast, after rigorous adjustment, uniform (across participants) and statistically significant longitudinal changes in all but one ECG parameter were observed in survivors with normal LV function. Healthy aging was characterized by a slight decrease in QRS-T angle (1°/3 years) and SVG azimuth, and a slight increase in SAI QRS-T (1-2 mV*ms/3 years), Cornell product (20 mm*ms/3 years), QTc (1.3 ms/3 years), and SVG elevation and magnitude. The degree of heterogeneity in ECG changes across healthy aging participants was small. QRS duration was an exception, however; after full adjustment, there were no statistically significant longitudinal trends in QRS duration in healthy aging participants ( Figure 6 ). Longitudinal Model 1 was adjusted for age, sex, and race. Model 2 was additionally adjusted for coronary heart disease (CHD), heart failure (HF), hypertension, diabetes mellitus, BMI, smoking, presence of ventricular conduction abnormalities, and heart rate and systolic and diastolic blood pressure measured at the time of echocardiography. Model 3 in addition was adjusted for QRS duration. Heat map color coded the most significant findings (largest effect size and R 2 and smallest P value) as red. Color transitioned to the least significant findings (smallest effect size and R
2
, and the largest/less significant P value) as green. changes in QRS duration were fully explained by subclinical myocardial injury not only in LV dysfunction but also in a healthy aging group.
Comparison of Longitudinal ECG Trends in Participants With Different Modes of Death and LV Dysfunction Over 12-Year Follow-Up
Longitudinal changes in ECG parameters in ARIC cohort participants with different causes of death, in comparison to surviving participants, (Figure 7 ; Figure XIII in the Data Supplement) showed that cardiac death victims experienced the fastest GEH worsening (Table IV in the Data Supplement). The pattern of ECG changes in SCD victims and victims of non-SCD was similar to that as described above for individuals with LV dysfunction (Figure 6 ). The major difference between these subgroups was in the speed of GEH worsening; although SCD victims were characterized by rapid worsening of GEH over time, those who developed LV dysfunction demonstrated slow progression of GEH worsening. One additional distinct feature of healthy aging was the opposite direction of SVG azimuth changes over time (decreasing square-root SVG azimuth; Figure 7D ). Because of shorter follow-up (median 12 versus 24 years), longitudinal analysis II had less statistical power compared with longitudinal analysis I, which explains the wider confidence intervals in Figure 7 . However, point estimates reported by both longitudinal analyses were consistent.
DISCUSSION
In this large biracial community-based cohort of elderly individuals, we demonstrated, in both cross-sectional and longitudinal analyses, that GEH was associated with echocardiographic measures of cardiac structure and function. These findings confirm the concept that electrophysiological properties in general, and the GEH phenotype specifically, reflect subclinical abnormalities in cardiac structure and function and represents one mechanism by which abnormal electrophysiological substrate may lead to an increased risk of LV dysfunction and SCD. Together with clinical characteristics, GEH ECG parameters explained up to one third of variability in LV structure and function, confirming the use of assessing cardiac electrophysiological properties to better understand cardiac electromechanical pump physiology. Clear differences in GEH observed ≈25 years before diagnosed LV dysfunction and distinct patterns of gradually increasing GEH were independently associated with LV systolic dysfunction, dilatation, and hypertrophy. Slowly worsening GEH parameters were associated with , echocardiographic LV hypertrophy (echo-LVH; magenta), abnormal LV end-diastolic volume index (LVEDVi; blue), and abnormal LV end-systolic volume index (LVESVi; purple). Model 1 (square) was adjusted by sex and race. Model 2 (circle) was in addition adjusted for prevalent and incident heart failure and coronary heart disease. Model 3 (diamond) was further adjusted for all time-updated covariates (diabetes mellitus, hypertension, body mass index, current smoking status, total cholesterol, high-density lipoprotein, triglycerides, systolic and diastolic blood pressure, heart rate, presence of ventricular conduction abnormalities, high-sensitivity cTnT [cardiac troponin T] and NT-proBNP [N-terminal pro-B-type natriuretic peptide], and age), and exact time interval (in days) between each ECG recording. subsequent LV dysfunction, whereas SCD victims were characterized by rapidly worsening GEH parameters. Observing longitudinal changes in GEH over time offers opportunities for preventive interventions, and this should be further explored in future prospective clinical trials. Longitudinal GEH changes in participants with LV dysfunction are likely explained by underlying CVD and subclinical myocardial injury. Importantly, our study described a distinct pattern of longitudinal changes in SVG azimuth in healthy aging participants. Altogether, our study provided evidence of a potential vicious cycle of abnormal GEH leading to LV dysfunction, which in turn further exacerbates GEH abnormalities.
Vicious Cycle of GEH and LV Dysfunction
We observed a distinct longitudinal association of SVG direction (SVG azimuth) with normal LV function over a median of 25 years of follow-up in spite of the presence of traditional risk factors. 28 This observation supports the hypothesis of a primary effect (either favorable or unfavorable) of SVG direction on electromechanical pump function. If favorable, it diminishes the influence of traditional risk factors and potentially counteracts subclinical myocardial injury, preserving LV function. In the case of abnormal GEH, it may facilitate development of LV dysfunction, promote deleterious effects of traditional cardiovascular risk factors and subclinical injury, and facilitate progression of CVD substrate. In turn, this progressive CVD substrate may worsen GEH. As we observed, the degree of GEH abnormalities were significantly larger in participants with CVD, and the strength of correlation between LV function measures and GEH measures was stronger in participants with LV dysfunction. Further study of the mechanism of SVG direction effect on cardiac electrophysiology is warranted.
GEH Is a Marker of Early Subclinical Myocardial Injury
We observed that adjustment for CVD, its risk factors, and subclinical myocardial injury (high-sensitivity cTnT and proBNP) fully explained longitudinal trends in participants with developing LV dysfunction. Therefore, GEH can serve as a marker of subclinical myocardial injury. Previous studies have demonstrated a longitudinal association between high-sensitivity cTnI (cardiac troponin I) and SAI QRS-T 29 in HF patients, which is consistent with our findings.
Differences Between SCD and LV Dysfunction in Longitudinal Trend of GEH Progression
Our findings help to explain differences in the risk of SCD and the risk of progressive LV dysfunction. Rapidly worsening GEH is associated with increased SCD risk, whereas slowly worsening GEH is associated with increased risk of developing LV dysfunction. We previously reported an increased risk of SCD associated with large GEH changes over time. 6 This finding underscored importance of serial GEH monitoring because one single measure of GEH might not be sufficient for discrimination of the risk of SCD from non-SCD.
GEH and LV Systolic Function
In our study, QRS duration had the strongest crosssectional association with LVEF, whereas SAI QRS-T had the strongest independent association with GLS. Altogether, GEH explained ≈10% of systolic function variability in cross-sectional analysis. An inverse relationship between QRS duration and systolic function has been reported in the Framingham Heart Study. 30 GLS is more sensitive than LVEF for detection of myocardial dysfunction and prediction of adverse cardiovascular outcomes. 31, 32 Our findings confirm an association between global ECG measures (both traditional and novel) and LV systolic function. However, the weakto-negligible strength of the association suggests that electric and mechanical domains cannot be considered interchangeable and should be viewed as complementary characteristics of cardiac electromechanical function. Longitudinally increasing QRS-T angle, SAI QRS-T, and changing SVG direction were strongly associated with LV systolic dysfunction. Early detection of subclinical CVD is crucially important for successful prevention of overt CVD and adverse CV outcomes. Further studies are needed to assess how GEH changes in response to cardiovascular medications and lifestyle modifications. Additionally, in the future, automated GEH measurement can be easily implemented into routine clinical 12-lead ECG analysis, and this could enable widespread GEH monitoring for the early detection of abnormal electrophysiological substrate, which might then trigger further testing or treatment.
GEH and Cardiac Structure
Several studies have shown a positive association between LV size (diameter, volumes, and length) and QRS duration. 30, 33, 34 In this study, SAI QRS-T, sex-specific Cornell product, and QRS duration had the strongest association with LV size and mass. Consistent with previous findings of QRS duration studies, 30, 33, 34 the strength of association between LV structure and GEH was moderate. Agreement between ECG-LVH and LV mass has been extensively studied. 35 ECG-LVH predicts cardiovascular outcomes independent of LV mass. [36] [37] [38] Our observation of a moderate association between GEH and LV mass and size supports the concept of independent electrophysiological substrate, 6 which only moderately correlates with LV size and mass.
Results of this study potentially explain previously reported discrepancies between ECG-LVH and LV mass. 35 We observed that the association between Cornell product and LVMi was significantly stronger in blacks, compared with whites, in younger participants, and in those with smaller body mass index. These observed interactions should be considered in the interpretation of ECG-LVH. Of note, we observed that Cornell product was the strongest longitudinal predictor of LVMi, even if measured 25 years before observation of echo-LVH. Thus, a false-positive ECG-LVH could be considered as an early preclinical stage of LVMi increase. This hypothesis should be tested in a prospective study with longitudinal echocardiographic assessment.
Comparison of ECG Parameters
Few prior studies have evaluated associations between QRS-T angle and cardiac structure and function. 39, 40 This study is the first comprehensive cross-sectional and longitudinal evaluation of traditional and novel ECG parameters, uncovering differences between traditional ECG parameters and various GEH metrics.
Our study clarifies differences between SAI QRS-T and Cornell product. Both parameters incorporate QRS complex duration and voltage and, therefore, correlate with each other. 6 However, this study demonstrated that in longitudinal analysis, SAI QRS-T did not predict echo-LVH, whereas Cornell product did. Consistently, SAI QRS-T was more strongly associated with LV volumes in hypertension-free participants compared with hypertensive participants, suggesting that LVH confounds SAI QRS-T interpretation. In our study, SAI QRS-T was the strongest longitudinal predictor of LV dilatation. Prospective longitudinal study of LV volumes is needed to study longitudinal relationships between SAI QRS-T and LV geometry. The strong association of SAI QRS-T with LV volumes (and geometry of the heart) could be explained by the solid angle theorem. 41 Across all studied ECG metrics, QRS duration stood out as the strongest cross-sectional marker of LV structure and systolic function (especially LVEF) in all participants, but especially in the subgroup with HF. At the same time, however, QRS duration, in contrast to all other studied ECG parameters, did not maintain an independent longitudinal trend over time. The patterns of longitudinal changes in QRS duration in both healthy aging and LV dysfunction subgroups was fully explained by CVD risk factors and subclinical myocardial injury. Therefore, QRS duration likely reflects the end result of the effect of myocardial injury on electrophysiological substrate, whereas, in contrast, GEH likely reflects the cause of myocardial injury. This hypothesis should be further tested in a longitudinal study of LV mechanical function. QRS duration and LVEF are excellent predictors of global and cardiac mortality, but the degree of increased risk for SCD in subjects with increased QRS duration and LVEF is similar to the magnitude of increased total cardiac mortality risk. If there were a mechanistic link between QRS duration/LVEF and SCD, patients with increased QRS duration/decreased LVEF should have risk for SCD increased out of proportion to their total cardiac mortality risk, which have not been shown. [42] [43] [44] 
Strengths and Limitations
Several limitations of the study should be noted. Because of the nature of observational analyses, we cannot rule out the possibility of residual confounding. Although we conducted longitudinal ECG analyses, we were not able to conduct longitudinal analysis of the cardiac structure and function, and therefore, we cannot determine the exact timing of LV dysfunction onset. Nevertheless, robust longitudinal analyses of ECG changes over time allowed us to characterize differences in longitudinal trends in individuals who experienced different outcomes and for the first time to describe SVG direction changes over time, likely contributing to the maintenance of cardiovascular health in spite of exposure to CVD risk factors. Baseline clinical characteristics of ARIC visit 5 responders and nonresponders differed significantly, which could also reduce the generalizability of the study findings. However, in spite of greater exposure to CVD risk factors at baseline, visit 5 responders and nonresponders had similar GEH parameters except for SVG magnitude and SAI QRS-T. Racial and sex differences in visit 5 responders versus nonresponders reinforce the importance of enriching future studies of GEH with women and blacks.
In summary, in a large cohort of middle-aged and elderly men and women, we observed that although most echocardiographic measures of cardiac structure and function are in the range of normal values, increasing GEH over time is associated with higher LV mass and volume and worsening LV systolic function. These associations are independent of demographic characteristics and prevalent and subclinical CVD. GEH is a strong and more sensitive longitudinal predictor of cardiac structure and function compared with traditional global ECG parameters. Increasing GEH represents a potential mechanism of LV dysfunction. Continuous, long-term monitoring of GEH using ECG patches 45 in the future may allow early identification of subclinical myocardial injury, which potentially could assist in prompting timely interventions to improve patient outcomes. QRS duration stands out as the ECG marker having the strongest cross-sectional association with today's LV structure and function, but it does not change over time in a clinically relevant way.
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